JP2005525377A5 - - Google Patents

Download PDF

Info

Publication number
JP2005525377A5
JP2005525377A5 JP2003574181A JP2003574181A JP2005525377A5 JP 2005525377 A5 JP2005525377 A5 JP 2005525377A5 JP 2003574181 A JP2003574181 A JP 2003574181A JP 2003574181 A JP2003574181 A JP 2003574181A JP 2005525377 A5 JP2005525377 A5 JP 2005525377A5
Authority
JP
Japan
Prior art keywords
composition
peripheral neuropathy
desmethyl
selegiline
desmethyl selegiline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003574181A
Other languages
Japanese (ja)
Other versions
JP2005525377A (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/006690 external-priority patent/WO2003075906A1/en
Publication of JP2005525377A publication Critical patent/JP2005525377A/en
Publication of JP2005525377A5 publication Critical patent/JP2005525377A5/ja
Pending legal-status Critical Current

Links

Claims (26)

大線維末梢神経障害（ｌａｒｇｅ−ｆｉｂｅｒ ｐｅｒｉｐｈｅｒａｌ ｎｅｕｒｏｐａｔｈｙ）の予防または処置の必要のある被験体において、大線維末梢神経障害を予防または処置するための組成物であって、該組成物は以下：
該大線維末梢神経障害と関連する症状の１つ以上を、予防、減少、または排除するのに十分な量のデスメチルセレジリンを含有する、組成物。 A composition for preventing or treating large fiber peripheral neuropathy in a subject in need of prevention or treatment of large-fiber peripheral neuropathy, the composition comprising:
A composition comprising an amount of desmethyl selegiline sufficient to prevent, reduce or eliminate one or more of the symptoms associated with said large fiber peripheral neuropathy. 前記大線維末梢神経障害が、大線維感覚神経障害（ｌａｒｇｅ−ｆｉｂｅｒ ｓｅｎｓｏｒｙ ｎｅｕｒｏｐａｔｈｙ）である、請求項１に記載の組成物。 The composition according to claim 1, wherein the large fiber peripheral neuropathy is a large-fiber sensory neuropathy. 前記大線維末梢神経障害が、大線維運動神経障害（ｌａｒｇｅ−ｆｉｂｅｒ ｍｏｔｏｒ ｎｅｕｒｏｐａｔｈｙ）である、請求項１に記載の組成物。 2. The composition of claim 1, wherein the large fiber peripheral neuropathy is a large-fiber motor neuropathy. 前記大線維末梢神経障害が、糖尿病性神経障害の発現である、請求項１に記載の組成物。 The composition of claim 1, wherein the large fiber peripheral neuropathy is manifestation of diabetic neuropathy. 前記大線維末梢神経障害が、化学療法剤によって引き起こされる、請求項１に記載の組成物。 The composition of claim 1, wherein the large fiber peripheral neuropathy is caused by a chemotherapeutic agent. 前記化学療法剤が、癌治療のために投与される、請求項５に記載の組成物。 6. The composition of claim 5, wherein the chemotherapeutic agent is administered for cancer treatment. 前記デスメチルセレジリンが、Ｒ（−）エナンチオマーの形態であり、かつＳ（＋）エナンチオマーが実質的に存在していない、請求項１に記載の組成物。 2. The composition of claim 1, wherein the desmethyl selegiline is in the form of the R (-) enantiomer and is substantially free of the S (+) enantiomer. 前記デスメチルセレジリンが、Ｓ（＋）エナンチオマーの形態であり、かつＲ（−）エナンチオマーが実質的に存在していない、請求項１に記載の組成物。 The composition of claim 1, wherein the desmethyl selegiline is in the form of an S (+) enantiomer and is substantially free of the R (−) enantiomer. 前記デスメチルセレジリンが、胃腸管からのデスメチルセレジリン吸収を回避する経路で投与されるように処方される、請求項１に記載の組成物。 2. The composition of claim 1, wherein the desmethyl selegiline is formulated to be administered by a route that avoids desmethyl selegiline absorption from the gastrointestinal tract. 前記デスメチルセレジリンが、頬側、舌下、または非経口投与されるように処方される、請求項９に記載の組成物。 10. The composition of claim 9, wherein the desmethyl selegiline is formulated for buccal, sublingual or parenteral administration. 前記デスメチルセレジリンが、経皮投与されるように処方される、請求項９に記載の組成物。 10. The composition of claim 9, wherein the desmethyl selegiline is formulated for transdermal administration. 前記被験体がヒトである、請求項１に記載の組成物。 The composition of claim 1, wherein the subject is a human. 前記デスメチルセレジリンが、遊離アミンの重量に基づいて、１日あたり０．０１ｍｇ／ｋｇと１日あたり０．１５ｍｇ／ｋｇとの間の用量で投与されるように処方される、請求項１に記載の組成物。 2. The desmethyl selegiline is formulated to be administered at a dose between 0.01 mg / kg per day and 0.15 mg / kg per day based on the weight of free amine. A composition according to 1 . 小線維末梢神経障害（ｓｍａｌｌ−ｆｉｂｅｒ ｐｅｒｉｐｈｅｒａｌ ｎｅｕｒｏｐａｔｈｙ）の予防または処置の必要のある被験体において、小線維末梢神経障害を予防または処置するための組成物であって、該組成物は以下：
該小線維末梢神経障害と関連する症状の１つ以上を、予防、減少、または排除するのに十分な量のデスメチルセレジリンを含有する、組成物。 In a subject in need of prevention or treatment of small-fiber peripheral neuropathy, a composition for preventing or treating small-fiber peripheral neuropathy, the composition comprising:
A composition comprising an amount of desmethyl selegiline sufficient to prevent, reduce or eliminate one or more of the symptoms associated with the fibril peripheral neuropathy. 前記小線維末梢神経障害が、異常な機能または小さな有髄軸索の病理学的変化から生じる、請求項１４に記載の組成物。 15. The composition of claim 14, wherein the fibrillar peripheral neuropathy results from abnormal function or pathological changes in small myelinated axons. 前記小線維末梢神経障害が、異常な機能または小さな無髄軸索の病理学的変化から生じる、請求項１４に記載の組成物。 15. The composition of claim 14, wherein the small fiber peripheral neuropathy results from abnormal function or pathological changes of small unmyelinated axons. 前記小線維末梢神経障害が、糖尿病性神経障害の発現である、請求項１４に記載の組成物。 15. The composition of claim 14, wherein the small fiber peripheral neuropathy is a manifestation of diabetic neuropathy. 前記小線維末梢神経障害が、化学療法剤によって引き起こされる、請求項１４に記載の組成物。 15. The composition of claim 14, wherein the small fiber peripheral neuropathy is caused by a chemotherapeutic agent. 前記化学療法剤が、癌治療のために投与される、請求項１８に記載の組成物。 19. The composition of claim 18, wherein the chemotherapeutic agent is administered for cancer treatment. 前記デスメチルセレジリンが、Ｒ（−）エナンチオマーの形態であり、かつＳ（＋）エナンチオマーが実質的に存在していない、請求項１４に記載の組成物。 15. The composition of claim 14, wherein the desmethyl selegiline is in the form of the R (-) enantiomer and is substantially free of the S (+) enantiomer. 前記デスメチルセレジリンが、Ｓ（＋）エナンチオマーの形態であり、かつＲ（−）エナンチオマーが実質的に存在していない、請求項１４に記載の組成物。 15. The composition of claim 14, wherein the desmethyl selegiline is in the form of an S (+) enantiomer and is substantially free of the R (-) enantiomer. 前記デスメチルセレジリンが、胃腸管からのデスメチルセレジリン吸収を回避する経路で投与されるように処方される、請求項１４に記載の組成物。 15. The composition of claim 14, wherein the desmethyl selegiline is formulated to be administered by a route that avoids desmethyl selegiline absorption from the gastrointestinal tract. 前記デスメチルセレジリンが、頬側、舌下、または非経口投与されるように処方される、請求項２２に記載の組成物。 23. The composition of claim 22, wherein the desmethyl selegiline is formulated for buccal, sublingual or parenteral administration. 前記デスメチルセレジリンが、経皮投与されるように処方される、請求項２２に記載の組成物。 23. The composition of claim 22, wherein the desmethyl selegiline is formulated for transdermal administration. 前記被験体がヒトである、請求項１４に記載の組成物。 15. The composition of claim 14, wherein the subject is a human. 前記デスメチルセレジリンが、遊離アミンの重量に基づいて、１日あたり０．０１ｍｇ／ｋｇと１日あたり０．１５ｍｇ／ｋｇとの間の用量で投与されるように処方される、請求項１４に記載の組成物。 15. The desmethyl selegiline is formulated to be administered at a dose between 0.01 mg / kg per day and 0.15 mg / kg per day based on the weight of free amine. A composition according to 1 .
JP2003574181A 2002-03-04 2003-03-04 Method for prevention and treatment of peripheral neuropathy by administration of desmethyl selegiline Pending JP2005525377A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36160902P 2002-03-04 2002-03-04
PCT/US2003/006690 WO2003075906A1 (en) 2002-03-04 2003-03-04 Methods for preventing and treating peripheral neuropathy by administering desmethylselegiline

Publications (2)

Publication Number Publication Date
JP2005525377A JP2005525377A (en) 2005-08-25
JP2005525377A5 true JP2005525377A5 (en) 2006-04-13

Family

ID=27805055

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003574181A Pending JP2005525377A (en) 2002-03-04 2003-03-04 Method for prevention and treatment of peripheral neuropathy by administration of desmethyl selegiline

Country Status (7)

Country Link
EP (1) EP1487427A4 (en)
JP (1) JP2005525377A (en)
CN (2) CN100506220C (en)
CA (1) CA2478026A1 (en)
HK (1) HK1080716A1 (en)
MX (1) MXPA04008574A (en)
WO (1) WO2003075906A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008507586A (en) * 2004-07-26 2008-03-13 テバ ファーマシューティカル インダストリーズ リミティド Pharmaceutical administration containing rasagrine
WO2009066685A1 (en) * 2007-11-19 2009-05-28 Snow Brand Milk Products Co., Ltd. Sense-improving agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3764144D1 (en) * 1986-04-16 1990-09-13 Asta Pharma Ag SYNERGISTIC COMBINATION OF AMANTADINE AND SELEGILINE.
WO1996022068A2 (en) * 1995-01-13 1996-07-25 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
WO1997033572A1 (en) * 1996-03-15 1997-09-18 Somerset Pharmaceuticals, Inc. Method for preventing and treating peripheral neurophathy by administering selegiline
US6417160B1 (en) * 1997-10-14 2002-07-09 Nadine A. Tatton Methods for increasing schwann cell survival

Similar Documents

Publication Publication Date Title
JP2007530703A5 (en)
JP2021100937A5 (en)
Chadwick et al. Manipulation of brain serotonin in the treatment of myoclonus
JP2005518433A5 (en)
EA200600327A1 (en) BENZIMIDAZOLONE COMPOUNDS WITH AGONISTIC ACTIVITY AGAINST 5-NTRECEPTORS
JP2003509349A5 (en)
JP2005528325A5 (en)
CA2472954A1 (en) Aza-arylpiperazines
JP2007505099A5 (en)
TW200628152A (en) Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorsers
DE69739415D1 (en) Carbone acids and their derivatives and pharmaceutical compositions containing them
JP2005508840A5 (en)
JP2006503850A5 (en)
JP2019529541A5 (en)
JP2004506682A5 (en)
JP2005512965A5 (en)
JP2005525377A5 (en)
JP2008542414A5 (en)
JP2007509960A5 (en)
JP2009535410A5 (en)
WO2002072086A8 (en) Use of epigallocatechin-3-gallate or its derivatives in the prevention and treatment of neurodegenerative diseases
KR950701623A (en) Substituted hexahydrobenzophenanthridine
RU2008124830A (en) Rapamycin Derivative or IMPDH Inhibitor for the Treatment of Polycystic Kidney Disease
JP2005516907A5 (en)
CA2234936A1 (en) Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine